APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaginosis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Vaginosis Drug Industry Research Report 2026

22 December 2025137 pages

Choose your research edition.

Industry ResearchVaginosis Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaginosis Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Vaginosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaginosis Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaginosis Drug Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Vaginosis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Vaginosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Vaginosis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Vaginosis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Vaginosis Drug include Yunnan Baiyao, Abbott, Xiuzheng, Teva, Sanofi, Pfizer, Bayer, West-Ward and Starpharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Vaginosis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Vaginosis Drug Market by Company

Yunnan Baiyao

Abbott

Xiuzheng

Teva

Sanofi

Pfizer

Bayer

West-Ward

Starpharma

Piramal

Perrigo

Novel

Mission

HPGC

Galderma

Edenvridge

Alkem

Vaginosis Drug Segment by Type

Rx

OTC

Vaginosis Drug Segment by Application

Hospital

Pharmacy

Other

Vaginosis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaginosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaginosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaginosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Vaginosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Vaginosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Vaginosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vaginosis Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Vaginosis Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Vaginosis Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Vaginosis Drug Revenue of Manufacturers (2021-2026) Table 9. Global Vaginosis Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Vaginosis Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Vaginosis Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Vaginosis Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Vaginosis Drug, Product Type & Application Table 14. Global Vaginosis Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Vaginosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Yunnan Baiyao Company Information Table 19. Yunnan Baiyao Business Overview Table 20. Yunnan Baiyao Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Yunnan Baiyao Vaginosis Drug Product Portfolio Table 22. Yunnan Baiyao Recent Developments Table 23. Abbott Company Information Table 24. Abbott Business Overview Table 25. Abbott Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Abbott Vaginosis Drug Product Portfolio Table 27. Abbott Recent Developments Table 28. Xiuzheng Company Information Table 29. Xiuzheng Business Overview Table 30. Xiuzheng Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Xiuzheng Vaginosis Drug Product Portfolio Table 32. Xiuzheng Recent Developments Table 33. Teva Company Information Table 34. Teva Business Overview Table 35. Teva Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Teva Vaginosis Drug Product Portfolio Table 37. Teva Recent Developments Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Sanofi Vaginosis Drug Product Portfolio Table 42. Sanofi Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Pfizer Vaginosis Drug Product Portfolio Table 47. Pfizer Recent Developments Table 48. Bayer Company Information Table 49. Bayer Business Overview Table 50. Bayer Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Bayer Vaginosis Drug Product Portfolio Table 52. Bayer Recent Developments Table 53. West-Ward Company Information Table 54. West-Ward Business Overview Table 55. West-Ward Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. West-Ward Vaginosis Drug Product Portfolio Table 57. West-Ward Recent Developments Table 58. Starpharma Company Information Table 59. Starpharma Business Overview Table 60. Starpharma Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Starpharma Vaginosis Drug Product Portfolio Table 62. Starpharma Recent Developments Table 63. Piramal Company Information Table 64. Piramal Business Overview Table 65. Piramal Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Piramal Vaginosis Drug Product Portfolio Table 67. Piramal Recent Developments Table 68. Perrigo Company Information Table 69. Perrigo Business Overview Table 70. Perrigo Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Perrigo Vaginosis Drug Product Portfolio Table 72. Perrigo Recent Developments Table 73. Novel Company Information Table 74. Novel Business Overview Table 75. Novel Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Novel Vaginosis Drug Product Portfolio Table 77. Novel Recent Developments Table 78. Mission Company Information Table 79. Mission Business Overview Table 80. Mission Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Mission Vaginosis Drug Product Portfolio Table 82. Mission Recent Developments Table 83. HPGC Company Information Table 84. HPGC Business Overview Table 85. HPGC Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. HPGC Vaginosis Drug Product Portfolio Table 87. HPGC Recent Developments Table 88. Galderma Company Information Table 89. Galderma Business Overview Table 90. Galderma Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Galderma Vaginosis Drug Product Portfolio Table 92. Galderma Recent Developments Table 93. Edenvridge Company Information Table 94. Edenvridge Business Overview Table 95. Edenvridge Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Edenvridge Vaginosis Drug Product Portfolio Table 97. Edenvridge Recent Developments Table 98. Alkem Company Information Table 99. Alkem Business Overview Table 100. Alkem Vaginosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Alkem Vaginosis Drug Product Portfolio Table 102. Alkem Recent Developments Table 103. Global Vaginosis Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Vaginosis Drug Sales by Region (2021-2026) & (k units) Table 105. Global Vaginosis Drug Sales Market Share by Region (2021-2026) Table 106. Global Vaginosis Drug Sales by Region (2027-2032) & (k units) Table 107. Global Vaginosis Drug Sales Market Share by Region (2027-2032) Table 108. Global Vaginosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Vaginosis Drug Revenue Market Share by Region (2021-2026) Table 110. Global Vaginosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Vaginosis Drug Revenue Market Share by Region (2027-2032) Table 112. North America Vaginosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 114. North America Vaginosis Drug Sales by Country (2027-2032) & (k units) Table 115. North America Vaginosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Vaginosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Vaginosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 119. Europe Vaginosis Drug Sales by Country (2027-2032) & (k units) Table 120. Europe Vaginosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Vaginosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Vaginosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 124. Asia Pacific Vaginosis Drug Sales by Country (2027-2032) & (k units) Table 125. Asia Pacific Vaginosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Vaginosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Vaginosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 129. South America Vaginosis Drug Sales by Country (2027-2032) & (k units) Table 130. South America Vaginosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Vaginosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Vaginosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 134. Middle East and Africa Vaginosis Drug Sales by Country (2027-2032) & (k units) Table 135. Middle East and Africa Vaginosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Vaginosis Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Vaginosis Drug Sales by Type (2021-2026) & (k units) Table 138. Global Vaginosis Drug Sales by Type (2027-2032) & (k units) Table 139. Global Vaginosis Drug Sales Market Share by Type (2021-2026) Table 140. Global Vaginosis Drug Sales Market Share by Type (2027-2032) Table 141. Global Vaginosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Vaginosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Vaginosis Drug Revenue Market Share by Type (2021-2026) Table 144. Global Vaginosis Drug Revenue Market Share by Type (2027-2032) Table 145. Global Vaginosis Drug Price by Type (2021-2026) & (US$/unit) Table 146. Global Vaginosis Drug Price by Type (2027-2032) & (US$/unit) Table 147. Global Vaginosis Drug Sales by Application (2021-2026) & (k units) Table 148. Global Vaginosis Drug Sales by Application (2027-2032) & (k units) Table 149. Global Vaginosis Drug Sales Market Share by Application (2021-2026) Table 150. Global Vaginosis Drug Sales Market Share by Application (2027-2032) Table 151. Global Vaginosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Vaginosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Vaginosis Drug Revenue Market Share by Application (2021-2026) Table 154. Global Vaginosis Drug Revenue Market Share by Application (2027-2032) Table 155. Global Vaginosis Drug Price by Application (2021-2026) & (US$/unit) Table 156. Global Vaginosis Drug Price by Application (2027-2032) & (US$/unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Vaginosis Drug Distributors List Table 160. Vaginosis Drug Customers List Table 161. Vaginosis Drug Industry Trends Table 162. Vaginosis Drug Industry Drivers Table 163. Vaginosis Drug Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Vaginosis Drug Product Image Figure 5. Global Vaginosis Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Vaginosis Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Vaginosis Drug Sales (2021-2032) & (k units) Figure 8. Global Vaginosis Drug Average Price (US$/unit) & (2021-2032) Figure 9. Rx Product Image Figure 10. OTC Product Image Figure 11. Hospital Product Image Figure 12. Pharmacy Product Image Figure 13. Other Product Image Figure 14. Global Vaginosis Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Vaginosis Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Vaginosis Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Vaginosis Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Vaginosis Drug Sales by Region in 2025 Figure 20. Global Vaginosis Drug Revenue by Region in 2025 Figure 21. North America Vaginosis Drug Market Size by Country in 2025 Figure 22. North America Vaginosis Drug Sales Market Share by Country (2021-2032) Figure 23. North America Vaginosis Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Vaginosis Drug Market Size by Country in 2025 Figure 28. Europe Vaginosis Drug Sales Market Share by Country (2021-2032) Figure 29. Europe Vaginosis Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Vaginosis Drug Market Size by Country in 2025 Figure 41. Asia Pacific Vaginosis Drug Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Vaginosis Drug Revenue Market Share by Country (2021-2032) Figure 43. China Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Vaginosis Drug Market Size by Country in 2025 Figure 52. South America Vaginosis Drug Sales Market Share by Country (2021-2032) Figure 53. South America Vaginosis Drug Revenue Market Share by Country (2021-2032) Figure 54. Brazil Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Vaginosis Drug Market Size by Country in 2025 Figure 58. Middle East and Africa Vaginosis Drug Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Vaginosis Drug Revenue Market Share by Country (2021-2032) Figure 60. Egypt Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Vaginosis Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Vaginosis Drug Sales Market Share by Type (2021-2032) Figure 66. Global Vaginosis Drug Revenue Market Share by Type (2021-2032) Figure 67. Global Vaginosis Drug Price (US$/unit) by Type (2021-2032) Figure 68. Global Vaginosis Drug Sales Market Share by Application (2021-2032) Figure 69. Global Vaginosis Drug Revenue Market Share by Application (2021-2032) Figure 70. Global Vaginosis Drug Price (US$/unit) by Application (2021-2032) Figure 71. Vaginosis Drug Value Chain Figure 72. Vaginosis Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Vaginosis Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Rx
  • OTC
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Yunnan Baiyao
  • Abbott
  • Xiuzheng
  • Teva
  • Sanofi
  • Pfizer
  • Bayer
  • West-Ward
  • Starpharma
  • Piramal
  • Perrigo
  • Novel
  • Mission
  • HPGC
  • Galderma
  • Edenvridge
  • Alkem

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Vaginosis Drug Market Size (2021-2032)
  4. 2.2.2 Global Vaginosis Drug Sales (2021-2032)
  5. 2.2.3 Global Vaginosis Drug Market Average Price (2021-2032)
  6. 2.3 Vaginosis Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Rx
  9. 2.3.3 OTC
  10. 2.4 Vaginosis Drug by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Pharmacy
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Vaginosis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Vaginosis Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Vaginosis Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Vaginosis Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Vaginosis Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Vaginosis Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Vaginosis Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Vaginosis Drug, Established Date
  9. 3.9 Global Vaginosis Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Yunnan Baiyao
  2. 4.1.1 Yunnan Baiyao Company Information
  3. 4.1.2 Yunnan Baiyao Business Overview
  4. 4.1.3 Yunnan Baiyao Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Yunnan Baiyao Vaginosis Drug Product Portfolio
  6. 4.1.5 Yunnan Baiyao Recent Developments
  7. 4.2 Abbott
  8. 4.2.1 Abbott Company Information
  9. 4.2.2 Abbott Business Overview
  10. 4.2.3 Abbott Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Abbott Vaginosis Drug Product Portfolio
  12. 4.2.5 Abbott Recent Developments
  13. 4.3 Xiuzheng
  14. 4.3.1 Xiuzheng Company Information
  15. 4.3.2 Xiuzheng Business Overview
  16. 4.3.3 Xiuzheng Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Xiuzheng Vaginosis Drug Product Portfolio
  18. 4.3.5 Xiuzheng Recent Developments
  19. 4.4 Teva
  20. 4.4.1 Teva Company Information
  21. 4.4.2 Teva Business Overview
  22. 4.4.3 Teva Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Teva Vaginosis Drug Product Portfolio
  24. 4.4.5 Teva Recent Developments
  25. 4.5 Sanofi
  26. 4.5.1 Sanofi Company Information
  27. 4.5.2 Sanofi Business Overview
  28. 4.5.3 Sanofi Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Sanofi Vaginosis Drug Product Portfolio
  30. 4.5.5 Sanofi Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer Vaginosis Drug Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 Bayer
  38. 4.7.1 Bayer Company Information
  39. 4.7.2 Bayer Business Overview
  40. 4.7.3 Bayer Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Bayer Vaginosis Drug Product Portfolio
  42. 4.7.5 Bayer Recent Developments
  43. 4.8 West-Ward
  44. 4.8.1 West-Ward Company Information
  45. 4.8.2 West-Ward Business Overview
  46. 4.8.3 West-Ward Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 West-Ward Vaginosis Drug Product Portfolio
  48. 4.8.5 West-Ward Recent Developments
  49. 4.9 Starpharma
  50. 4.9.1 Starpharma Company Information
  51. 4.9.2 Starpharma Business Overview
  52. 4.9.3 Starpharma Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Starpharma Vaginosis Drug Product Portfolio
  54. 4.9.5 Starpharma Recent Developments
  55. 4.10 Piramal
  56. 4.10.1 Piramal Company Information
  57. 4.10.2 Piramal Business Overview
  58. 4.10.3 Piramal Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Piramal Vaginosis Drug Product Portfolio
  60. 4.10.5 Piramal Recent Developments
  61. 4.11 Perrigo
  62. 4.11.1 Perrigo Company Information
  63. 4.11.2 Perrigo Business Overview
  64. 4.11.3 Perrigo Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Perrigo Vaginosis Drug Product Portfolio
  66. 4.11.5 Perrigo Recent Developments
  67. 4.12 Novel
  68. 4.12.1 Novel Company Information
  69. 4.12.2 Novel Business Overview
  70. 4.12.3 Novel Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Novel Vaginosis Drug Product Portfolio
  72. 4.12.5 Novel Recent Developments
  73. 4.13 Mission
  74. 4.13.1 Mission Company Information
  75. 4.13.2 Mission Business Overview
  76. 4.13.3 Mission Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Mission Vaginosis Drug Product Portfolio
  78. 4.13.5 Mission Recent Developments
  79. 4.14 HPGC
  80. 4.14.1 HPGC Company Information
  81. 4.14.2 HPGC Business Overview
  82. 4.14.3 HPGC Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 HPGC Vaginosis Drug Product Portfolio
  84. 4.14.5 HPGC Recent Developments
  85. 4.15 Galderma
  86. 4.15.1 Galderma Company Information
  87. 4.15.2 Galderma Business Overview
  88. 4.15.3 Galderma Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Galderma Vaginosis Drug Product Portfolio
  90. 4.15.5 Galderma Recent Developments
  91. 4.16 Edenvridge
  92. 4.16.1 Edenvridge Company Information
  93. 4.16.2 Edenvridge Business Overview
  94. 4.16.3 Edenvridge Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Edenvridge Vaginosis Drug Product Portfolio
  96. 4.16.5 Edenvridge Recent Developments
  97. 4.17 Alkem
  98. 4.17.1 Alkem Company Information
  99. 4.17.2 Alkem Business Overview
  100. 4.17.3 Alkem Vaginosis Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Alkem Vaginosis Drug Product Portfolio
  102. 4.17.5 Alkem Recent Developments
5 Global Vaginosis Drug Market Scenario by Region
  1. 5.1 Global Vaginosis Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Vaginosis Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Vaginosis Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Vaginosis Drug Sales by Region: 2027-2032
  5. 5.3 Global Vaginosis Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Vaginosis Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Vaginosis Drug Revenue by Region: 2027-2032
  8. 5.4 North America Vaginosis Drug Market Facts & Figures by Country
  9. 5.4.1 North America Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Vaginosis Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Vaginosis Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Vaginosis Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Vaginosis Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Vaginosis Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Vaginosis Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Vaginosis Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Vaginosis Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Vaginosis Drug Market Facts & Figures by Country
  41. 5.7.1 South America Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Vaginosis Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Vaginosis Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Vaginosis Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Vaginosis Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Vaginosis Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Vaginosis Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Vaginosis Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Vaginosis Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Vaginosis Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Vaginosis Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Vaginosis Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Vaginosis Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Vaginosis Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Vaginosis Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Vaginosis Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Vaginosis Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Vaginosis Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Vaginosis Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Vaginosis Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Vaginosis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Vaginosis Drug Value Chain Analysis
  2. 8.1.1 Vaginosis Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Vaginosis Drug Production Mode & Process
  5. 8.2 Vaginosis Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Vaginosis Drug Distributors
  8. 8.2.3 Vaginosis Drug Customers
9 Global Vaginosis Drug Analyzing Market Dynamics
  1. 9.1 Vaginosis Drug Industry Trends
  2. 9.2 Vaginosis Drug Industry Drivers
  3. 9.3 Vaginosis Drug Industry Opportunities and Challenges
  4. 9.4 Vaginosis Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst